The invention relates to an aqueous pharmaceutical composition comprising:a) bilastineor a pharmaceutically acceptable salt or solvate thereof,b) mometasone, or a pharmaceutically acceptable derivative thereof,c) a suspending agent, andd) 2-hydroxypropyl-β-cyclodextrin；wherein the pH of the aqueous pharmaceutical composition is between 3.5 and 5.5, and wherein the content of 2-hydroxypropyl-β-cyclodextrin is less than 8.5% by weight.The invention also relates to said compositions for use in the treatment and/or prevention of a disorder or disease susceptible to amelioration by antagonism of H1histamine receptor and/or of a corticosteroid-responsive disease through nasal administration.The invention also relates to a process for preparing the aqueous pharmaceutical composition above mentioned.本發明涉及一種水性藥物組成物，其包含：a)比拉斯汀或其藥學上可接受的鹽或溶劑化物b)莫米松或其藥學上可接受的衍生物，c)懸浮劑，d)2-羥丙基-β-環糊精；其中水性藥物組成物的pH係在3.5至5.5之間，並且其中2-羥丙基-β-環糊精的含量小於8.5重量%。本發明亦涉及該等組成物在經由鼻腔給藥治療和/或預防易藉由H1組織胺受體的拮抗作用改善的失調或疾病和/或皮質類固醇反應性疾病的用途。本發明亦涉及製備上述水性藥物組成物的方法。
